Welcome to the Ziconotide Source, an interactive Internet site intended for US audiences. This web site is designed to provide information to physicians and healthcare personnel on important and new aspects of ziconotide, a novel therapeutic modality to treat pain, currently under regulatory review at the US Food and Drug Administration (FDA).

Ziconotide is a novel non-opioid, non local anesthetic, developed for the treatment of severe chronic pain. Ziconotide (also previously referred to as CI 1009, or SNX-111) is the synthetic form of the cone snail peptide w-cenotoxin M-VII-A, a neurone-specific N-type calcium channel blocker that is being developed as an analgesic agent by Neurex Corporation (a subsidiary of Elan Corporation). The New Drug Application (NDA) for ziconotide, which was submitted on December 28, 1999, had been accepted as filed by the FDA. The FDA has agreed to a six-month review of this NDA.

This site is intended to provide the most recent information regarding Ziconotide. If you would like to be placed on our ziconotide.com mailing list, please register. This site is sponsored by DocMD.com, a new Internet site dedicated to bringing useful information to physicians and other healthcare personnel. Be sure to visit DocMD.com to keep up on what is new and interesting in healthcare, and for other helpful information. Please contact us at info@docmd.com if you have additional suggestions or comments.

This site is sponsored by DocMD.com, Inc.
© DocMD.com, 2000. All rights reserved.